{
    "Rank": 467,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT04403529",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "ZY(2018-2020)-CCCX-2005-04"
                },
                "Organization": {
                    "OrgFullName": "Fudan University",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer",
                "OfficialTitle": "Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "May 2020",
                "OverallStatus": "Recruiting",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "May 25, 2020",
                    "StartDateType": "Actual"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "May 31, 2024",
                    "PrimaryCompletionDateType": "Anticipated"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "May 31, 2024",
                    "CompletionDateType": "Anticipated"
                },
                "StudyFirstSubmitDate": "May 20, 2020",
                "StudyFirstSubmitQCDate": "May 24, 2020",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "May 27, 2020",
                    "StudyFirstPostDateType": "Actual"
                },
                "LastUpdateSubmitDate": "May 28, 2020",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "June 1, 2020",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Zhimin Shao",
                    "ResponsiblePartyInvestigatorTitle": "Head of Breast Surgery Department",
                    "ResponsiblePartyInvestigatorAffiliation": "Fudan University"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Fudan University",
                    "LeadSponsorClass": "OTHER"
                }
            },
            "OversightModule": {
                "IsFDARegulatedDrug": "No",
                "IsFDARegulatedDevice": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "This is a prospective, single site, randomized, double-blind Phase III clinical trial to evaluate the clinical value of Traditional Chinese Medicine in the adjuvant therapy of triple-negative breast cancer patients."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Triple Negative Breast Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "adjuvant therapy",
                        "traditional chinese medicine"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 3"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "Randomized",
                    "DesignInterventionModel": "Parallel Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "Double",
                        "DesignWhoMaskedList": {
                            "DesignWhoMasked": [
                                "Participant",
                                "Investigator"
                            ]
                        }
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "200",
                    "EnrollmentType": "Anticipated"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Traditional Chinese Medicine",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "60 days of oral Traditional Chinese Medicine (\"prescription for breast cancer\" Traditional Chinese Medicine formulation)",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Drug: Traditional Chinese Medicine Formulation"
                                ]
                            }
                        },
                        {
                            "ArmGroupLabel": "Placebo",
                            "ArmGroupType": "Placebo Comparator",
                            "ArmGroupDescription": "60 days of oral placebo (placebo contains 5% \"prescription for breast cancer\" Traditional Chinese Medicine formulation and 95% filler)",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Drug: Placebo Formulation"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "Traditional Chinese Medicine Formulation",
                            "InterventionDescription": "The \"prescription for breast cancer\" Traditional Chinese Medicine formulation is a combination of 12 herbal components and it is available in granules form to be dissolved in hot water for consumption.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Traditional Chinese Medicine"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "\"prescription for breast cancer\" Traditional Chinese Medicine formulation"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "Placebo Formulation",
                            "InterventionDescription": "Placebo granules contains 5% \"prescription for breast cancer\" Traditional Chinese Medicine formulation and 95% filler, it is available in granules form to be dissolved in hot water for consumption.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Placebo"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "Placebo granules contains 5% \"prescription for breast cancer\" Traditional Chinese Medicine formulation and 95% filler"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Disease free survival",
                            "PrimaryOutcomeTimeFrame": "3 years"
                        },
                        {
                            "PrimaryOutcomeMeasure": "Difference in quality of life scores as assessed by EORTC QLQ-C30",
                            "PrimaryOutcomeDescription": "Difference in quality of life scores as assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Higher scores mean a better outcome. An higher scores after treatment compared to baseline mean a better outcome or improvement.",
                            "PrimaryOutcomeTimeFrame": "2 months from baseline, and follow-up every 3 months afterwards until up to 3 years."
                        },
                        {
                            "PrimaryOutcomeMeasure": "Difference in quality of life scores as assessed by EORTC QLQ-BR23",
                            "PrimaryOutcomeDescription": "Difference in quality of life scores as assessed by European Organisation for Research and Treatment of Cancer quality of life questionnaire-breast cancer module 23 (QLQ-BR23). Higher scores mean a better outcome. An higher scores after treatment compared to baseline mean a better outcome or improvement.",
                            "PrimaryOutcomeTimeFrame": "2 months from baseline, and follow-up every 3 months afterwards until up to 3 years."
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Local recurrence rate",
                            "SecondaryOutcomeTimeFrame": "1,2,3 years"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Distant metastasis rate",
                            "SecondaryOutcomeTimeFrame": "1,2,3 years"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Overall survival",
                            "SecondaryOutcomeTimeFrame": "3 years"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Difference in Syndrome of Traditional Chinese Medicine Evaluation of Traditional Chinese Medicine syndromes",
                            "SecondaryOutcomeTimeFrame": "2 months from baseline, and follow-up every 3 months afterwards until up to 3 years."
                        },
                        {
                            "SecondaryOutcomeMeasure": "Difference in physical fitness evaluation by Eastern Cooperative Oncology Group (ECOG) score",
                            "SecondaryOutcomeDescription": "Difference in physical fitness evaluation by Eastern Cooperative Oncology Group (ECOG) score, the score runs from 0 to 5, with 0 denoting perfect health and 5 death.",
                            "SecondaryOutcomeTimeFrame": "2 months from baseline, and follow-up every 3 months afterwards until up to 3 years."
                        },
                        {
                            "SecondaryOutcomeMeasure": "Difference in physical fitness evaluation by Karnofsky performance score (KPS)",
                            "SecondaryOutcomeDescription": "Difference in physical fitness evaluation by Karnofsky performance score (KPS), the score runs from 0 to 100, with 100 denoting perfect health and 0 death.",
                            "SecondaryOutcomeTimeFrame": "2 months from baseline, and follow-up every 3 months afterwards until up to 3 years."
                        },
                        {
                            "SecondaryOutcomeMeasure": "Adverse events",
                            "SecondaryOutcomeDescription": "Incidence and Severity of adverse events according to the Common Terminology Criteria for Adverse Events Version 4.0\uff08CTCAE V4.0\uff09",
                            "SecondaryOutcomeTimeFrame": "2 months from baseline, and follow-up every 3 months afterwards until up to 3 years."
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nWomen aged 18-70 years old;\nPathologically confirmed stage I-III breast cancer after early breast cancer surgery, and is confirmed by histopathology to be triple negative breast cancer (estrogen receptor (ER)-negative/ progesterone receptor (PR)-negative/ human epidermal growth factor receptor 2 (HER2)-negative). HER2-negative is defined as a negative in situ hybridization test or an immunohistochemistry (IHC) status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization test is required by local laboratory testing;\nHas an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; life expectancy is \u2265 6 months;\nHas adequate organ function meeting the following criteria: (1) adequate bone marrow function: hemoglobin \u2265 90 g/L (no blood transfusion within 14 days); absolute neutrophil count \u2265 1.5 x 109 /L; platelet count \u2265 100 * 109 /L; (2)adequate liver and kidney function: Alanine Aminotransferase (ALT) \u2264 3\u00d7upper limit of normal (ULN), Aspartate Aminotransferase (AST) \u2264 3\u00d7ULN, Total Bilirubin (TBIL)\u2264 1.5\u00d7ULN, serum creatinine \u2264 1\u00d7ULN\uff0cand with endogenous creatinine clearance rate of >50 ml/min (Cockcroft-Gault formula).\nParticipant has completed the last of their post surgical radiotherapy and chemotherapy within the last 6 months before date of enrollment, and no tumor recurrence or metastasis at the time of enrollment.\nParticipants voluntarily joined the study, has signed informed consent before any trial related activities are conducted, has good compliance and has agreed to follow-up.\n\nExclusion Criteria:\n\nHas bilateral breast cancer;\nHas previous history of additional malignancy, with the exception of adequately treated basal cell carcinoma and cervical carcinoma in situ.\nHas metastatic (Stage 4) breast cancer;\nHas any >T4 lesion (UICC1987) (with skin involvement, mass adhesion and fixation, and inflammatory breast cancer);\nIs pregnant, is breast feeding women, or women of childbearing age who cannot practice effective contraceptives;\nPatients participating in other drug related clinical trials at the same time;\nHas severe organ dysfunction (cardiopulmonary liver and kidney) insufficiency, left ventricular ejection fraction (LVEF) < 50% (cardiac ultrasound); severe cardio cerebral vascular disease within the 6 months previous of randomization (such as unstable angina, chronic heart failure, uncontrolled hypertension with blood pressure>150/90mmgh, myocardial infarction, or cerebral blood vessel); diabetic patients with poor blood glucose control; patients with severe hypertension;\nHas known allergy to study medication;\nHas severe or uncontrolled infection;\nHas a history of psychotropic substance abuse and were unable to abandon drug habits, or those with history of mental disorders;\nThe researchers judged patients to be unsuitable for the study.",
                "HealthyVolunteers": "No",
                "Gender": "Female",
                "MinimumAge": "18 Years",
                "MaximumAge": "70 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "CentralContactList": {
                    "CentralContact": [
                        {
                            "CentralContactName": "ZhiMin Shao, MD, PhD",
                            "CentralContactRole": "Contact",
                            "CentralContactPhone": "+86-21-64175590",
                            "CentralContactPhoneExt": "8808",
                            "CentralContactEMail": "zhimingshao@yahoo.com"
                        }
                    ]
                },
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "ZhiMin Shao, MD, PhD",
                            "OverallOfficialAffiliation": "Fudan University",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Fudan University Shanghai Cancer Hospital",
                            "LocationStatus": "Recruiting",
                            "LocationCity": "Shanghai",
                            "LocationState": "Shanghai",
                            "LocationZip": "200032",
                            "LocationCountry": "China",
                            "LocationContactList": {
                                "LocationContact": [
                                    {
                                        "LocationContactName": "Zhi-Ming Shao, MD, PhD",
                                        "LocationContactRole": "Contact",
                                        "LocationContactPhone": "+86-021-64175590",
                                        "LocationContactPhoneExt": "8888",
                                        "LocationContactEMail": "zhimingshao@yahoo.com"
                                    }
                                ]
                            }
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000001943",
                            "ConditionMeshTerm": "Breast Neoplasms"
                        },
                        {
                            "ConditionMeshId": "D000064726",
                            "ConditionMeshTerm": "Triple Negative Breast Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000001941",
                            "ConditionAncestorTerm": "Breast Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012871",
                            "ConditionAncestorTerm": "Skin Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M4910",
                            "ConditionBrowseLeafName": "Breast Neoplasms",
                            "ConditionBrowseLeafAsFound": "Breast Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M30063",
                            "ConditionBrowseLeafName": "Triple Negative Breast Neoplasms",
                            "ConditionBrowseLeafAsFound": "Triple Negative Breast Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M4908",
                            "ConditionBrowseLeafName": "Breast Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M15364",
                            "ConditionBrowseLeafName": "Skin Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC17",
                            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        }
                    ]
                }
            }
        }
    }
}